Register

Support: 888-992-3836|NewsWire|Home|Login / Register

Home > Boards > US Listed > Biotechs > Affimed Therapeutics (AFMD)

I saw that and I was thinking that

Public Reply | Private Reply | Keep | Last Read

Next 10 | Previous | Next

Lynx5100

Followed By	2
Posts	146
Boards Moderated	0
Alias Born	03/17/14

160x600 placeholder

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 1/15/2021 4:27:32 PM

Affimed Announces Closing of Public Offering of Common Shares and Full Exercise of Underwriters’ Option to Purchase Additio... GlobeNewswire Inc. - 1/15/2021 9:21:32 AM

Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 1/14/2021 5:16:43 PM

Affimed Announces Pricing of $100,000,000 Public Offering of Common Shares GlobeNewswire Inc. - 1/13/2021 6:15:00 AM

Affimed Announces Proposed Public Offering of Common Shares GlobeNewswire Inc. - 1/12/2021 4:01:00 PM

Affimed to Present at the 39th Annual J.P. Morgan Healthcare Conference GlobeNewswire Inc. - 1/11/2021 6:45:00 AM

Affimed Announces €25 Million Debt Financing Agreement with Silicon Valley Bank GlobeNewswire Inc. - 1/11/2021 6:30:00 AM

Affimed Announces Pipeline and Business Update GlobeNewswire Inc. - 1/7/2021 6:30:00 AM

Statement of Ownership (sc 13g) Edgar (US Regulatory) - 12/18/2020 4:14:43 PM

Affimed Announces Updated AFM13 Clinical Data Presentation at the American Society of Hematology Annual Meeting, Demonstratin... GlobeNewswire Inc. - 12/7/2020 10:01:00 AM

Affimed Announces Publication of Final Study Results of its Innate Cell Engager Candidate AFM13 in Combination with MSD’s a... GlobeNewswire Inc. - 11/19/2020 4:01:00 PM

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 11/10/2020 8:22:47 AM

Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 11/10/2020 8:15:33 AM

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 11/10/2020 6:34:41 AM

Affimed Reports Third Quarter 2020 Financial Results and Highlights Recent Operational Progress GlobeNewswire Inc. - 11/10/2020 6:30:00 AM

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 11/9/2020 4:32:37 PM

Affimed and Roivant Sciences Announce Licensing and Strategic Collaboration Agreement to Develop and Commercialize Novel Inna... GlobeNewswire Inc. - 11/9/2020 4:01:00 PM

New Preclinical Data being Presented at SITC Underscore Promising Combinations of Affimed’s AFM13 and Cytokine-Activated Na... GlobeNewswire Inc. - 11/9/2020 8:20:00 AM

Artiva Biotherapeutics and Affimed Announce Platform-to-Platform R&D Collaboration for Targeted Off-the-Shelf NK Cell Therapi... GlobeNewswire Inc. - 11/5/2020 4:01:00 PM

Affimed Announces Presentations on its AFM13 Innate Cell Engager at the 62nd American Society of Hematology Annual Meeting an... GlobeNewswire Inc. - 11/4/2020 4:05:00 PM

Affimed to Present at Upcoming Investor Conferences GlobeNewswire Inc. - 11/4/2020 6:30:00 AM

Affimed to Report 3rd Quarter 2020 Financial Results & Corporate Update November 10, 2020 GlobeNewswire Inc. - 11/3/2020 6:30:00 AM

Affimed and NKMax America to Study the Combination of AFM24, an EGFR-Targeted Innate Cell Engager, with SNK01 Natural Killer ... GlobeNewswire Inc. - 10/20/2020 6:30:10 AM

Affimed and NKMax America to Study the Combination of AFM24, an EGFR-Targeted Innate Cell Engager, with SNK01 Natural Killer ... GlobeNewswire Inc. - 10/20/2020 6:30:00 AM

Affimed Announces Presentation of Preclinical Data on AFM13-targeted NK cells at the 35th Annual Meeting of the Society for I... GlobeNewswire Inc. - 10/14/2020 5:15:00 PM

Lynx5100	Tuesday, 07/14/20 04:19:51 PM
Re: MWM post# 219
Post # of 237

I saw that and I was thinking that might’ve taken a little wind out of our sale what do you think but I understand where you’re coming from but it could work both ways

Public Reply | Private Reply | Keep | Last Read

Next 10 | Previous | Next

Follow Board

Keyboard Shortcuts

Report TOS Violation

X


Current Price
Change
Volume
Detailed Quote - Discussion Board

+/- to Watchlist

Consent Preferences